Vanguard Global Advisers’s Oric Pharmaceuticals ORIC Stock Holding History
Bought
Maintained
Sold
Other funds holding ORIC
Vanguard Global Advisers's ORIC Position: Q3 2026 in Review
Vanguard Global Advisers increased its Oric Pharmaceuticals (ORIC) stake by 24% in Q3 2026, buying an estimated $85.1K and bringing the position to 35,130 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #2115.
Vanguard Global Advisers first reported a position in ORIC in Q1 2026 and has held it in 3 quarters since. The position peaked at $505K in Q1 2026. 203 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.
- Vanguard Global Advisers held 35,130 shares of Oric Pharmaceuticals worth $473K as of Q3 2026.
- Vanguard Global Advisers bought 6,833 Oric Pharmaceuticals shares in Q3 2026, an estimated $85.1K.
- Oric Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2115 holding.
- Vanguard Global Advisers first reported a position in Oric Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Oric Pharmaceuticals position peaked at $505K in Q1 2026.
- 203 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.